Managing postoperative atrial fibrillation after open-heart surgery using transdermal β
Bisono tape
Bisoprolol
Postoperative atrial fibrillation
Transdermal patch
beta-blockers
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
06 Apr 2023
06 Apr 2023
Historique:
received:
07
10
2022
accepted:
02
04
2023
medline:
10
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Postoperative atrial fibrillation (POAF) after open-heart surgery is a non-negligible complication. We aimed to describe the efficacy of a transdermal patch of bisoprolol for managing POAF and flutter in thoracic surgical procedures. We analyzed the data of 384 patients who underwent open-heart surgery at our hospital and received oral bisoprolol to prevent POAF. Among them, 65 patients (16.9%) also received a 4-mg transdermal patch of bisoprolol to control the heart rate due to POAF. We applied the bisoprolol transdermal patch when the heart rate was > 80 bpm and removed it at ≤ 60 bpm; an additional patch was applied when the heart rate was > 140 bpm. Heparin calcium injections were administered twice daily for anticoagulation between 2 and 6 days postoperatively. The average number of prescriptions for transdermal patches of bisoprolol during hospitalization was 1.8 ± 1.1 (1-5). The median first prescription date was on postoperative day 2 (range: days 0-37). Sinus rhythm recovered within 24 h in 18 patients (27.7%). Eight patients (12.3%) were switched to continuous landiolol infusion because of persistent tachycardia. In three patients, the transdermal patch was removed owing to severe bradycardia. Fifteen patients experienced persistent atrial fibrillation and were treated with electrical cardioversion during hospitalization. We did not observe any serious complications that could be directly attributed to bisoprolol transdermal patch use. Single-use bisoprolol transdermal patch may help control the heart rate during the initial treatment of POAF after open-heart surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Postoperative atrial fibrillation (POAF) after open-heart surgery is a non-negligible complication. We aimed to describe the efficacy of a transdermal patch of bisoprolol for managing POAF and flutter in thoracic surgical procedures.
METHODS
METHODS
We analyzed the data of 384 patients who underwent open-heart surgery at our hospital and received oral bisoprolol to prevent POAF. Among them, 65 patients (16.9%) also received a 4-mg transdermal patch of bisoprolol to control the heart rate due to POAF. We applied the bisoprolol transdermal patch when the heart rate was > 80 bpm and removed it at ≤ 60 bpm; an additional patch was applied when the heart rate was > 140 bpm. Heparin calcium injections were administered twice daily for anticoagulation between 2 and 6 days postoperatively.
RESULTS
RESULTS
The average number of prescriptions for transdermal patches of bisoprolol during hospitalization was 1.8 ± 1.1 (1-5). The median first prescription date was on postoperative day 2 (range: days 0-37). Sinus rhythm recovered within 24 h in 18 patients (27.7%). Eight patients (12.3%) were switched to continuous landiolol infusion because of persistent tachycardia. In three patients, the transdermal patch was removed owing to severe bradycardia. Fifteen patients experienced persistent atrial fibrillation and were treated with electrical cardioversion during hospitalization. We did not observe any serious complications that could be directly attributed to bisoprolol transdermal patch use.
CONCLUSIONS
CONCLUSIONS
Single-use bisoprolol transdermal patch may help control the heart rate during the initial treatment of POAF after open-heart surgery.
Identifiants
pubmed: 37024987
doi: 10.1186/s13019-023-02227-z
pii: 10.1186/s13019-023-02227-z
pmc: PMC10080838
doi:
Substances chimiques
Bisoprolol
Y41JS2NL6U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103Informations de copyright
© 2023. The Author(s).
Références
Cardiol Res Pract. 2014;2014:615987
pubmed: 24511410
N Engl J Med. 2019 Nov 14;381(20):1909-1917
pubmed: 31722151
Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56
pubmed: 6370540
Drugs. 2013 Jun;73(9):959-77
pubmed: 23760735
J Clin Hypertens (Greenwich). 2013 Nov;15(11):806-14
pubmed: 24119112
Kyobu Geka. 2017 Nov;70(12):971-977
pubmed: 29104194
Gen Thorac Cardiovasc Surg. 2019 Dec;67(12):1007-1013
pubmed: 31049816
SAGE Open Med. 2020 Feb 20;8:2050312120907817
pubmed: 32128207
J Thorac Cardiovasc Surg. 2014 Sep;148(3):772-91
pubmed: 25129583
JAMA. 2004 Apr 14;291(14):1720-9
pubmed: 15082699
Clin Exp Hypertens. 2020 Aug 17;42(6):539-544
pubmed: 32009474
N Engl J Med. 1997 Dec 18;337(25):1785-91
pubmed: 9400034
BMC Cardiovasc Disord. 2019 Dec 30;19(1):316
pubmed: 31888491